Eli Lilly (LLY)

AI-powered earnings call analysis for Eli Lilly. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Latest Episode

Q3 2026 Earnings

6:30 • 10/29/2026

Eli Lilly (LLY) - Q3 2026

0:00

6:30

Speed:

Q3 2026 Earnings

7:10 • 2026/10/29

Eli Lilly (LLY) - Q3 2026

0:00

7:10

Speed:

Q3 2026 Earnings

7:35 • 29/10/2026

Eli Lilly (LLY) - Q3 2026

0:00

7:35

Speed:

Q3 2026 Earnings

8:38 • 29/10/2026

Eli Lilly (LLY) - Q3 2026

0:00

8:38

Speed:

Q3 2026 Earnings

8:08 • 29.10.2026

Eli Lilly (LLY) - Q3 2026

0:00

8:08

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

6:30

Eli Lilly reported 39% Q3 revenue growth driven by strong Mounjaro/Zepbound uptake and Medicare GLP-1 bridge program success, raising FY 2026 guidance to $91-92B revenue and $35-36 EPS.

Q2 2026 Earnings

6:54

Eli Lilly delivered 48% revenue growth in Q2 2026 with Mounjaro and Zepbound driving momentum; raised full-year guidance to $85-87B.

Q1 2026 Earnings

7:28

Eli Lilly delivered 56% revenue growth in Q1 2026 driven by Mounjaro and Zepbound momentum, launched Koundeo for obesity with encouraging early uptake, and announced five positive Phase III trials plus four strategic acquisitions to expand its immunology, oncology, and neuroscience portfolios.